Context: In April 1994, the results of a Merck-sponsored study, the Scandinavian Simvastatin Survival Study, were announced. Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%. In 1995, Zocor and Mevacor both made Merck over US$1 billion. Endo was awarded the 2006 Japan Prize, and the Lasker-DeBakey Clinical Medical Research Award in 2008. For his "pioneering research into a new class of molecules" for "lowering cholesterol,"[sentence fragment]

Question: Who received the Laser-Debakey Clinical Medical Research Aware?
Answer: Endo

Question: How much money did Merk make in 1995?
Answer: over US$1 billion

Question: How many patients received Zocor?
Answer: 4,444

Question: What study did Merk sponsor in 1994?
Answer: Scandinavian Simvastatin Survival Study

Question: What did the study reveal after 5 years?
Answer: a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%

Question: What was the brand name of simvastatin?
Answer: Zocor

Question: Patients treated with Zocor had their cholesterol reduced by how much?
Answer: 35%

Question: How much did Zocor reduce the chance of dying from a heart attack?
Answer: 42%

Question: How much money did Merck make from sales of Zocor and Mevacor?
Answer: over US$1 billion

Question: Endo received what award in 2008?
Answer: Lasker-DeBakey Clinical Medical Research Award

Question: Who received the Zocor Research Reward?
Answer: Unanswerable

Question: How much money did Simvastatin make in 1995?
Answer: Unanswerable

Question: How many patients received Simvastatin?
Answer: Unanswerable

Question: What study did Merk sponsor in 2008?
Answer: Unanswerable

Question: What did the study reveal after 2 years?
Answer: Unanswerable